Discover
SVRA
Savara Inc.
6.23
1 x 4.47
2 x 7.93
bid
ask
+
0.17
2.86%
12:12 PM
timesize
| Ytd | 3.38% | |
| 1y | 196.84% |
6.08
day range
6.26
2.10
52 week range
7.00
| Open | 6.10 | Prev Close | 6.06 | Low | 6.08 | High | 6.26 | Mkt Cap | 1.28B |
| Vol | 300.58K | Avg Vol | 1.57M | EPS | -0.56 | P/E | N/A | Forward P/E | -20.61 |
| Beta | 0.27 | Short Ratio | 19.82 | Inst. Own | 104.22% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-13 | 50-d Avg | 5.28 | 200-d Avg | 5.17 | 1yr Est | 10.94 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-12 | 2026-03 | 0 | N/A | N/A | N/A |
| 2026-03-13 | 2025-12 | 0 | N/A | -0.01 | -8.33% |
| 2025-11-12 | 2025-09 | 0 | N/A | -0.01 | -7.69% |
| 2025-08-13 | 2025-06 | 0 | N/A | -0.02 | -16.67% |
| 2025-05-13 | 2025-03 | 0 | N/A | N/A | N/A |
| 2025-03-27 | 2024-12 | 0 | N/A | -0.02 | -18.18% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2025-12-23 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2025-12-18 | Wells Fargo | Upgrade | Overweight | Overweight |
| 2025-11-14 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2025-11-13 | Citizens | Upgrade | Market Outperform | Market Outperform |
| 2025-10-23 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
| 2025-09-09 | Guggenheim | Upgrade | Buy | Buy |
Profile
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-12-08 | ELAM NEVAN C | Director | 106.89K | Stock Award(Grant) |
| 2024-12-11 | ERICKSON ANNE | Officer | 434.67K | Stock Award(Grant) |
| 2025-12-08 | HAWKINS RICHARD JAMES | Director | 161.33K | Stock Award(Grant) |
| 2026-06-21 | LOWRANCE DAVID L. CPA | Chief Financial Officer | 536.03K | Sale |
| 2024-12-11 | LUTZ ROBERT MATTHEW | Chief Operating Officer | 400.00K | Stock Award(Grant) |
| 2026-02-12 | MCCRACKEN JOSEPH S | Director | 302.64K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | NEA Management Company, LLC | 24.47M | 148.30M | 11.94% |
| 2026-03-30 | Bain Capital Life Sciences Investors, LLC | 17.60M | 106.66M | 8.59% |
| 2026-03-30 | Venrock Adviser, LLC | 13.74M | 83.27M | 6.71% |
| 2026-03-30 | Deerfield Management Company, L.P | 13.57M | 82.23M | 6.62% |
| 2026-03-30 | TCG Crossover Management, LLC | 12.36M | 74.91M | 6.03% |
| 2026-03-30 | Blackrock Inc. | 11.29M | 68.42M | 5.51% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 6.07M | 36.80M | 2.96% |
| 2026-05-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.89M | 23.54M | 1.90% |
| 2026-04-29 | iShares Trust-iShares Russell 2000 ETF | 3.43M | 20.82M | 1.68% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.51M | 9.16M | 0.74% |
| 2026-04-29 | Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.45M | 8.79M | 0.71% |
| 2026-04-29 | iShares Trust-iShares Russell 2000 Growth ETF | 1.20M | 7.26M | 0.58% |
Split
| Split | Date |
|---|---|
| 0 : 1 | 2017-04-28 |
| 0.04 : 1 | 2010-04-26 |